Author Archives: Scalper1

Shire Buying Rare-Disease Rival Dyax For $5.9 Billion

British drugmaker Shire (SHPG) agreed to pay $5.9 billion in cash for orphan-drug specialist Dyax (DYAX) Monday, sending the latter’s stock up sharply in early trading. Shire will pay $37.30 a share for Dyax, a premium of nearly 36% on Dyax’s Friday closing price. The deal includes a contingent value right (CVR) of $4 a share, or $646 million total, on Dyax’s drug candidate DX-2930, which is about to enter phase-three testing for hereditary

Sprint Milestone: Seen Adding Phone Subscribers

Sprint’s (S) fiscal Q2 loss is expected to narrow from the year-earlier quarter despite a 4% decline in revenue, as the SoftBank-controlled wireless firm is expected add postpaid phone customers for the first time since Q4 2010. Sprint’s $1-per-month lease plan — with an Apple (AAPL) iPhone 6 trade-in — has pressured market leaders Verizon Communications (VZ) and AT&T (T)to offer phone leasing plans of their own. T-Mobile (TMUS) reported surging